ライブラリ登録: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

年間 6 号発行

ISSN 印刷: 0743-4863

ISSN オンライン: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Emerging Role of Vesicular Carriers for Therapy of Visceral Leishmaniasis: Conventional versus Novel

巻 27, 発行 6, 2010, pp. 461-507
DOI: 10.1615/CritRevTherDrugCarrierSyst.v27.i6.10
Get accessGet access

要約

Visceral leishmaniasis (VL) is a systemic protozoan infection that infects a million people living in subtropical and tropical areas. Drugs are the major treatment available against this fatal infection. Conventional chemotherapy of VL involves treatment with pen- tavalent antimonials, pentamidine, paromomycin, miltefosine, etc., but this treatment is challenging because of the failure of drugs to penetrate macrophages where the parasite hides, toxic side effects, and drug resistance due to incomplete treatment schedules. The newer therapeutic approach of combination therapy employing multi-drug combinations provides improved treatment of VL because the combination reduces length of treatment, relapse, and risk of toxicity and increases the therapeutic index. Although considerable success has been attained using combination therapies, none has yet achieved commercial status. Therefore, there is an urgent need of designing novel, site-specific leishmanicidal drug carriers for safe and effective management of VL. Colloidal carriers such as liposomes, niosomes, emulsomes, and their engineered versions offer superior therapeutic efficacy over the conventional treatment in terms of site-specific drug delivery related to absolute treatment of disease with reduced side effects and toxicity. The control over spatial and sequential distribution of drug molecules after systemic or localized administration represents the major dispute in drug-delivery systems, and this can be resolved by the use of these colloidal carriers. The present review describes current conventional and combination drug therapies with special consideration given to the emerging role of novel vesicular colloidal carriers designed against VL. Colloidal carriers employing drugs in combination could lead to reductions in the duration of conventional treatment, better patient compliance, and the prevention of anti-leishmanial drug resistance or toxicity.

によって引用された
  1. Asthana Shalini, Gupta Pramod K, Chaurasia Mohini, Dube Anuradha, Chourasia Manish K, Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos, Expert Opinion on Drug Delivery, 10, 12, 2013. Crossref

  2. Seke Etet Paul F., Fawzi Mahomoodally M., New Insights in Staging and Chemotherapy of African Trypanosomiasis and Possible Contribution of Medicinal Plants, The Scientific World Journal, 2012, 2012. Crossref

  3. Gupta Swati, Pathak Yashwant, Gupta Manish K., Vyas Suresh P., RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted, Artificial Cells, Nanomedicine, and Biotechnology, 47, 1, 2019. Crossref

  4. Elsheikh Manal A., Rizk Samar A., Elnaggar Yosra S. R., Abdallah Ossama Y., Nanoemulsomes for Enhanced Oral Bioavailability of the Anticancer Phytochemical Andrographolide: Characterization and Pharmacokinetics, AAPS PharmSciTech, 22, 7, 2021. Crossref

  5. Rizk Samar A, Elsheikh Manal A, R Elnaggar Yosra S, Abdallah Ossama Y, Novel bioemulsomes for baicalin oral lymphatic targeting: development, optimization and pharmacokinetics, Nanomedicine, 16, 22, 2021. Crossref

  6. Gupta Mahima, Pathak Atul, Pathak Yashwant V., Gupta Swati, Introduction to Pharmacology of Macrophages with Drug Delivery Perspective, in Macrophage Targeted Delivery Systems, 2022. Crossref

  7. Abbas Haidy, Gad Heba A., El Sayed Nesrine S, Rashed Laila Ahmed, Khattab Mohamed A., Noor Ahmad O., Zewail Mariam, Development and Evaluation of Novel Leflunomide SPION Bioemulsomes for the Intra-Articular Treatment of Arthritis, Pharmaceutics, 14, 10, 2022. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain